Genscript Biotech (1548) H1 2026 earnings summary

Executive summary

• Revenue for the first half of 2026 reached $404.2 million, up 27.3% year-over-year, with adjusted net profit surging 203.3% to $62.5 million; core business net profit rose 116.7% to $25.6 million, while reported net loss narrowed to $129.3 million due to equity accounting impacts from Legend Group.

• Growth was driven by AI-driven demand, expansion of the gene-to-protein platform, and operational efficiency gains across all business segments.

• The company is positioned as a critical infrastructure provider for AI-enabled biotech innovation, with a diversified global customer base and strong balance sheet.

• Operating leverage, innovation, and global expansion accelerated profitability and margin expansion.

• Three main business segments: Life Science Group (78% of revenue), ProBio (14.4%), and Bestzyme (7.5%).

Financial highlights

• Group revenue reached $404.2 million, up 27.3% year-over-year; gross profit was $206.7 million, up 48%.

• Adjusted net profit hit $62.5 million, up 203.3% year-over-year; net loss was $129.3 million, improved from $181.9 million loss.

• Life Science Group revenue grew 28.8% to $319 million; ProBio revenue rose 34.2% to $61.1 million; Bestzyme revenue increased 7.4% to $30.4 million.

• Adjusted gross margin for Life Science Group reached 57.8% (55.4% excluding U.S. tariff refunds); adjusted operating margin was 29.5% (27.1% excluding refunds).

• Loss per share: (5.92) US cents.

Outlook and guidance

• Full-year guidance for Life Science Service segment raised: revenue growth expected at 25%-30%, adjusted gross margin above 55%, and adjusted operating margin above 25%.

• ProBio revenue growth guidance increased to 25%-30%, with positive EBITDA targeted for 2027.

• Bestzyme expected to achieve 8%-10% revenue growth and maintain adjusted gross margin over 43%.

• Continued strategic investments in gene-to-protein platform, automation, and digitalization to support AI-driven drug discovery.

• Sufficient resources and liquidity to support planned capital investments.